Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood KW, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2017 Feb 9;19(1):17. doi: 10.1186/s13058-017-0809-6. No abstract available.


Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.

Bria E, Furlanetto J, Carbognin L, Brunelli M, Caliolo C, Nortilli R, Massari F, Pedron S, Manfrin E, Pellini F, Bonetti F, Sperduti I, Pollini GP, Scarpa A, Tortora G.

Clin Breast Cancer. 2015 Feb;15(1):16-23. doi: 10.1016/j.clbc.2014.05.004. Epub 2014 Jun 23.


Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.

Chen JY, Li CF, Kuo CC, Tsai KK, Hou MF, Hung WC.

Breast Cancer Res. 2014 Jul 25;16(4):410. doi: 10.1186/s13058-014-0410-1.


Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.

Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ.

Mod Pathol. 2010 Jul;23(7):1029-39. doi: 10.1038/modpathol.2010.84. Epub 2010 May 14.


Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.

Takano Y, Takenaka H, Kato Y, Masuda M, Mikami T, Saegusa M, Okayasu I.

J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):505-12.


Association of genetic variation in mitotic kinases with breast cancer risk.

Wang X, Fredericksen ZS, Vierkant RA, Kosel ML, Pankratz VS, Cerhan JR, Justenhoven C, Brauch H; GENICA Consortium, Olson JE, Couch FJ.

Breast Cancer Res Treat. 2010 Jan;119(2):453-62. doi: 10.1007/s10549-009-0404-3. Epub 2009 Apr 30.


CHFR-associated early G2/M checkpoint defects in breast cancer cells.

Erson AE, Petty EM.

Mol Carcinog. 2004 Jan;39(1):26-33.


Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.

Wu Y, Zhuo X, Dai Z, Guo X, Wang Y, Zhang C, Lai L.

Mol Biosyst. 2015 Feb;11(2):497-505. doi: 10.1039/c4mb00610k.


Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G.

Breast Cancer Res. 2008;10(5):R81. doi: 10.1186/bcr2150. Epub 2008 Sep 29.


DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.

Jun DW, Hwang M, Kim YH, Kim KT, Kim S, Lee CH.

Oncotarget. 2016 Apr 5;7(14):17699-710. doi: 10.18632/oncotarget.7135.


Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance.

Löffler H, Fechter A, Matuszewska M, Saffrich R, Mistrik M, Marhold J, Hornung C, Westermann F, Bartek J, Krämer A.

Cancer Res. 2011 Mar 15;71(6):2129-39. doi: 10.1158/0008-5472.CAN-10-2684.


Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer.

Loddo M, Andryszkiewicz J, Rodriguez-Acebes S, Stoeber K, Jones A, Dafou D, Apostolidou S, Wollenschlaeger A, Widschwendter M, Sainsbury R, Tudzarova S, Williams GH.

J Pathol. 2014 Aug;233(4):344-56. doi: 10.1002/path.4393.


Structure meets function--centrosomes, genome maintenance and the DNA damage response.

Löffler H, Lukas J, Bartek J, Krämer A.

Exp Cell Res. 2006 Aug 15;312(14):2633-40. Epub 2006 Jun 20. Review.


Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.

BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163.


Induction of centrosome amplification during arsenite-induced mitotic arrest in CGL-2 cells.

Yih LH, Tseng YY, Wu YC, Lee TC.

Cancer Res. 2006 Feb 15;66(4):2098-106.


Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells.

Montañez-Wiscovich ME, Shelton MD, Seachrist DD, Lozada KL, Johnson E, Miedler JD, Abdul-Karim FW, Visvader JE, Keri RA.

J Pathol. 2010 Nov;222(3):271-81. doi: 10.1002/path.2762.


Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN.

Breast Cancer Res Treat. 2012 Sep;135(2):433-44. doi: 10.1007/s10549-012-2171-9. Epub 2012 Jul 24.


Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.


Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability.

Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E.

Clin Cancer Res. 2006 Jan 15;12(2):405-10.

Supplemental Content

Support Center